华丽家族拟战略性增资海和药物

Group 1 - Huayi Family Co., Ltd. plans to invest up to 300 million yuan in Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. through a share placement at a price of 4.75 yuan per share, acquiring no more than 63.157895 million shares [2] - After the investment, Huayi Family is expected to hold between 5% and 8.09% of Haihe Pharmaceutical's shares, with its controlling shareholder holding approximately 11.54% of Haihe Pharmaceutical's shares [2] - Haihe Pharmaceutical, established in 2011, focuses on the discovery, development, production, and commercialization of innovative drugs in the oncology field, with three products already commercialized and five in clinical research [2] Group 2 - The investment is seen as a strategic financial investment based on the long-term development potential of innovative drugs, aiming to achieve reasonable financial returns while ensuring stable operations of Huayi Family's main business [3] - The innovative drug market has been rapidly developing, with many pharmaceutical companies achieving significant economic benefits through research and development [3] - Huayi Family aims to explore opportunities in emerging industries through this investment in Haihe Pharmaceutical [3]